Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Active not recruiting × capmatinib × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Terminated 3 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 71 Nivolumab 38 Cyclophosphamide 37 Carboplatin 28 Specimen Handling 22 durvalumab 21 Paclitaxel 21 Dexamethasone 21 Lenalidomide 20 venetoclax 19 Gemcitabine 19 Radiotherapy 18 Magnetic Resonance Spectroscopy 18 Rituximab 17 Doxorubicin 16 fludarabine 15 Ipilimumab 15 Bevacizumab 15 atezolizumab 14 Biopsy 14 Vincristine 13 Etoposide 12 Cisplatin 12 Azacitidine 12 olaparib 11 Pemetrexed 11 Calcium Dobesilate 11 Oxaliplatin 10 Docetaxel 10 fludarabine phosphate 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05488314 2026-04-13

METalmark

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡